Skip to main content
OpenTrials
Completed

NCT Number: NCT07628556

Antidiabetic Medications and Risk of Cancer

A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Neoplasms Nutritional and Metabolic Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pécs

Pécs, 7634, Hungary

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Antidiabetic medication initiators

Exclusion criteria

  • Antidiabetic prescription in the previous 5 years
  • Recent pancreatectomy (previous or subsequent 90 days after inclusion)

Treatment and study plan

metformin

Drug

Metformin monotherapy

Sulphonylurea

Drug

SU monotherapy

DPP-4 inhibitor

Drug

DPP-4 inhibitor monotherapy

GLP-1 Receptor Agonists

Drug

GLP-1 Receptor Agonist monotherapy

SGLT-2 inhibitor

Drug

SGLT-2 inhibitor monotherapy

Insulin

Drug

Insulin monotherapy

MET + SU

Drug

MET + SU combination

MET + DPP-4 inhibitor

Drug

MET + DPP-4 inhibitor combination

MET + GLP-1RA

Drug

MET + GLP-1RA combination

MET + SGLT2i

Drug

MET + SGLT2i combination

MET + INS

Drug

MET + insulin combination

Primary outcomes

  1. Overall cancer risk

    Time frame: 2016-2022

Other outcomes

  1. Risk of lung cancer

    Time frame: 2016-2022

  2. Risk of colorectal cancer

    Time frame: 2016-2022

  3. Risk of pancreas cancer

    Time frame: 2016-2022

  4. Risk of urinary cancer

    Time frame: 2016-2022

  5. Risk of breast cancer

    Time frame: 2016-2022

  6. Risk of prostate cancer

    Time frame: 2016-2022

  7. Risk of hematological cancer

    Time frame: 2016-2022

  8. Risk of upper GI cancer

    Time frame: 2016-2022

  9. Risk of liver cancer

    Time frame: 2016-2022

  10. Risk of ovarian cancer

    Time frame: 2016-2022

  11. Risk of other types of cancer

    Time frame: 2016-2022

Sponsors and collaborators

Lead sponsor

University of Pecs

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 5, 2026
Registry last updated
Jun 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.